Improving nocturnal event monitoring in people with intellectual disability in community using an artificial intelligence camera.
Artificial intelligence
Developmental disabilities
Risk mitigation
SUDEP
Seizure deduction technology
Journal
Epilepsy & behavior reports
ISSN: 2589-9864
Titre abrégé: Epilepsy Behav Rep
Pays: United States
ID NLM: 101750909
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
02
2023
revised:
17
04
2023
accepted:
19
04
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
There is higher prevalence of epilepsy and SUDEP in people with intellectual disability (PwID) compared to general population. Accurate seizure recording particularly at night can be challenging in PwID. Neuro Event Labs seizure monitoring (Nelli) uses high-quality video based artificial intelligence to detect and record possible nocturnal seizures. This study looks to evaluate the clinical utility and acceptability of Nelli in PwID and epilepsy. Family/carers of PwID and drug resistant epilepsy with suspicions of nocturnal seizures who had not tolerated routine or ambulatory EEGs were invited to evaluate Nelli. Relevant demographics and clinical characteristics were collected. Nelli's impact, it's facilitators, barriers and feedback quality was captured from patient and professional stakeholders. Quantitative and thematic analysis was undertaken. Fifteen PwID and epilepsy and four health professionals were involved. Nelli recorded 707 possible seizure events across the study cohort of which 247 were not heard or recognised by carers. Carers recorded 165 episodes of 'restless' or "seizure behaviour" which the Nelli did not deem to be seizures. There was 93% acceptability. Thematic analysis revealed three broad themes of device acceptability, result implementation and possible seizure recognition ability. Nelli allowed for improved communication and care planning in a hitherto difficult to investigate population.
Identifiants
pubmed: 37152695
doi: 10.1016/j.ebr.2023.100603
pii: S2589-9864(23)00021-7
pmc: PMC10160340
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100603Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Seizure. 2014 May;23(5):382-5
pubmed: 24630808
Seizure. 2019 Feb;65:65-71
pubmed: 30616221
Neurol Clin Pract. 2023 Feb;13(1):e200117
pubmed: 36891282
Epilepsia. 2021 Sep;62(9):e135-e139
pubmed: 34254664
Expert Opin Pharmacother. 2020 Feb;21(2):173-181
pubmed: 31790280
Sci Rep. 2022 Nov 15;12(1):19571
pubmed: 36379994
Epilepsy Behav. 2018 Sep;86:200-203
pubmed: 30007785
Seizure. 2015 Jul;29:46-62
pubmed: 26076844
Brain Behav. 2022 Sep;12(9):e2737
pubmed: 35939047
Br J Psychiatry. 2022 Aug;221(2):488-493
pubmed: 35249557
Epilepsia. 2022 Feb 23;:
pubmed: 35194778
Seizure. 2015 Feb;25:112-6
pubmed: 25457453
Cochrane Database Syst Rev. 2020 Apr 2;4:CD011792
pubmed: 32239759
Br J Psychiatry. 2023 May;222(5):191-195
pubmed: 36786124
J Neurol. 2023 Apr 6;:
pubmed: 37022478
Br J Clin Pharmacol. 2023 Apr 14;:
pubmed: 37060156
Neurol Sci. 2021 Apr;42(4):1301-1309
pubmed: 33471259
J Epilepsy Res. 2020 Jun 30;10(1):8-17
pubmed: 32983950
Seizure. 2009 Sep;18(7):524-9
pubmed: 19592270
Epilepsy Res. 2021 Jan;169:106486
pubmed: 33310414
Epilepsy Behav. 2022 Aug;133:108804
pubmed: 35753111
J Neurol. 2022 May;269(5):2750-2760
pubmed: 35067759